James Appleman
Company: Primmune Therapeutics, Inc.
Job title: Co- Founder, Chief Scientific Officer, Senior Vice- President & Director - Research & Development
Seminars:
PRTX007, A Novel Orally Administered TLR7 Agonist Prodrug from Primmune Therapeutics for the Treatment of Serious Human Diseases 1:30 pm
day: Conference Day 2